SLS · NASDAQ · STOCK
SELLAS Life Sciences Group (SLS) Stock Analysis
$11.65
52W $1.39 – $15.88
54/100
$2.17B
-55.1
2.57
Is SLS Bullish or Bearish?
Mixed.
Innellis AI committee rates SELLAS Life Sciences Group, Inc. (SLS) Watch with a composite score of 54/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.97 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.03 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Growth Analyst remains cautious — 2 consecutive earnings misses -- execution concerns. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 7.6x prices in significant intangible value — Value
- ROE of only -35.9% -- cheap may mean cheap for a reason — Value
- 2 consecutive earnings misses -- execution concerns — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
54/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 72%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 7.6x prices in significant intangible value
Growth Analyst
bearish
20
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 52.4 to 54.0.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Technical Analyst: score 48->58 (+10); +1 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
49.9
Neutral
MACD Histogram
0.004
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$9.19
Resistance
$15.65
Bollinger %B
0.55
Inside Bands
Price vs Moving Averages
EMA 9
$11.54
Above
EMA 21
$11.82
Below
EMA 50
$11.93
Below
EMA 200
$8.74
Above
Fundamental Analysis
Valuation
67
Growth
62
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-55.1×
P/B Ratio
16.01×
PEG Ratio
-1.20
Dividend Yield
0.00%
52W High
$15.88
52W Low
$1.39
Quality & Growth
ROE
-3790.4%
ROA
-3428.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of -55.1 (inexpensive relative to a 15-40x range); Price-to-book of 16.0x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -37.9%; Return on assets of -34.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 18.83 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is negative (-0.15); Most recent quarter missed estimates by 9.9%; 2 consecutive earnings misses; EPS growth roughly steady (+0.0% -> +0.0% QoQ); Average YoY EPS growth of 28.6%; Analyst estimates rising over recent quarters
Get the Full SLS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →